Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EBIT (2020 - 2025)

Treace Medical Concepts' EBIT history spans 6 years, with the latest figure at -$5.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 2802.94% year-over-year to -$5.9 million; the TTM value through Dec 2025 reached -$54.2 million, up 2.75%, while the annual FY2025 figure was -$54.2 million, 2.75% up from the prior year.
  • EBIT reached -$5.9 million in Q4 2025 per TMCI's latest filing, up from -$15.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$204000.0 in Q4 2024 to a low of -$21.4 million in Q2 2024.
  • Average EBIT over 5 years is -$10.6 million, with a median of -$11.6 million recorded in 2022.
  • Peak YoY movement for EBIT: crashed 8566.67% in 2021, then surged 96.99% in 2024.
  • A 5-year view of EBIT shows it stood at -$5.6 million in 2021, then soared by 37.52% to -$3.5 million in 2022, then tumbled by 93.94% to -$6.8 million in 2023, then soared by 96.99% to -$204000.0 in 2024, then tumbled by 2802.94% to -$5.9 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's EBIT are -$5.9 million (Q4 2025), -$15.7 million (Q3 2025), and -$17.0 million (Q2 2025).